Eli Lilly has signed a new research deal with BigHat Biosciences to co-develop next-generation antibody therapeutics, as the ...

SAN DIEGO, March 23, 2025 — Glucagon-like peptide-1 (GLP-1 ... system that “paints” these peptides directly on the antibodies they target. In studies with mice, the system led to sustained ...

Five scientists won this year’s Breakthrough Prize in Life Sciences for their work on GLP-1 and the development of drugs for diabetes and obesity.

a novel anti-proprotein convertase subtilisin/kexin type 9 enzyme monoclonal antibody; IBI-362, a glucagon-like peptide-1 receptor/glucagon receptor dual agonist; and IBI-112, a novel long-acting ...

Opko Health and Entera Bio have formalized their partnership as the biotechs prepare to take the first orally administered dual agonist glucagonlike-peptide 1 (GLP-1)/glucagon peptide into the clinic.

a long-acting injectable glucagon-like-peptide-1 that is in Phase 3 clinical trial to treat short bowel syndrome. The company is developing NM-136, a humanized monoclonal antibody for the ...

UBT251, a so-called “triple G” agonist, targets GLP-1, gastric inhibitory polypeptide (GIP) and glucagon ... a collaboration with Laekna for an antibody to treat obesity.

a novel anti-proprotein convertase subtilisin/kexin type 9 enzyme monoclonal antibody; IBI-362, a glucagon-like peptide-1 receptor/glucagon receptor dual agonist; and IBI-112, a novel long-acting ...

New Antibody Test Improves Celiac Disease Diagnosis ... of immune cell that appears to travel to the pancreas to stimulate glucagon secretion, in the first evidence of a complex neuroimmune ...

stimulates liver cells to take up glucose from the blood and Glucagon: released from pancreas, stimulates liver cells to release glucose into the blood Antibodies Part of the immune system.